Facial EMG as an index of affective response to nicotine.
Negative affect reduction has been postulated to be a key feature of cigarette smoking. In the present study, facial electromyography (EMG), heart rate (HR), and skin conductance response (SCR) were used to evaluate the affective significance of acute nicotine administration and overnight withdrawal. Smokers (N = 115) attended four 90-min laboratory assessment sessions scheduled approximately 3 days apart. The sessions provided a complete crossing of 2 prelaboratory deprivation conditions (12-hr deprived vs. nondeprived) with 2 drug conditions (nicotine vs. placebo nasal spray). During each session, smokers viewed affective slides while facial EMG, HR, and SCR were recorded. Results indicated that for women, nicotine nasal spray resulted in lower corrugator EMG activity during both smoking-deprived and nondeprived sessions, compared with placebo. However, nondeprived women also showed an increase in zygomaticus EMG when given nicotine compared with placebo spray, whereas smoking-deprived women demonstrated a decrease in the zygomaticus response to nicotine compared with placebo. With men, nicotine also appeared to lower corrugator during deprivation, but not nondeprivation, compared with placebo spray, though the contrast only approached significance. With zygomaticus EMG, nicotine spray decreased men's zygomaticus responding during nondeprivation but not during deprivation, compared with placebo spray. The HR results reflected the stimulatory properties of the drug rather than nicotine's affective properties, whereas SCR was unresponsive to our experimental manipulations. The corrugator EMG results support negative reinforcement models of smoking that postulate that acute nicotine use reduces withdrawal-driven negative affect.
Robinson
Jason D
JD
Department of Behavioral Science, University of Texas M. D. Anderson Cancer Center, Houston, TX 77230, USA. jdrobinson@mdanderson.org
Cinciripini
Paul M
PM
Carter
Brain L
BL
Lam
Cho Y
CY
Wetter
David W
DW
D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000339:Affect / Q000187:drug effects*; D004562:Electrocardiography / Q000187:drug effects* / Q000379:methods; D005152:Facial Muscles / Q000187:drug effects* / Q000502:physiology; D005260:Female; D005712:Galvanic Skin Response / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009538:Nicotine / Q000008:administration & dosage*; D018722:Nicotinic Agonists / Q000008:administration & dosage*; D012737:Sex Factors; D012907:Smoking / Q000473:pathology* / Q000503:physiopathology; D016540:Smoking Cessation / Q000379:methods
D018722:Nicotinic Agonists; D009538:Nicotine
Addiction. 1999 Mar;94(3):327-40
10605857
Drug Alcohol Depend. 1996 Nov;42(3):209-15
8912804
Annu Rev Psychol. 1989;40:191-225
2648975
Nicotine Tob Res. 2006 Jun;8(3):361-9
16801294
Can J Exp Psychol. 2003 Sep;57(3):152-66
14596474
Psychophysiology. 1986 May;23(3):272-82
3749407
Addiction. 2001 Sep;96(9):1349-56
11672499
J Consult Clin Psychol. 1990 Feb;58(1):85-92
2319049
Addict Behav. 2007 Mar;32(3):543-61
16842931
Pharmacol Biochem Behav. 1992 Jun;42(2):301-11
1631184
Psychophysiology. 1986 Sep;23(5):567-89
3809364
Psychophysiology. 1989 May;26(3):311-20
2756080
Psychophysiology. 2000 Jan;37(1):13-20
10705763
Psychophysiology. 1995 Sep;32(5):436-43
7568637
Am Heart J. 1993 Mar;125(3):818-23
8438711
Int J Neuropsychopharmacol. 2001 Dec;4(4):371-6
11806862
Percept Mot Skills. 1994 Jun;78(3 Pt 1):787-800
8084692
Psychophysiology. 1993 May;30(3):279-86
8497557
J Consult Clin Psychol. 1994 Feb;62(1):141-6
8034816
Soc Sci Med. 1983;17(16):1107-23
6623118
J Health Soc Behav. 1980 Dec;21(4):383-8
7204932
Int J Psychophysiol. 2004 Jan;51(2):143-53
14693364
Addict Behav. 1984;9(3):265-71
6496202
J Pers Soc Psychol. 1986 Feb;50(2):260-8
3701577
Psychol Bull. 1984 Jan;95(1):52-77
6242437
Exp Clin Psychopharmacol. 1999 Aug;7(3):250-6
10472513
Psychophysiology. 1987 May;24(3):278-85
3602283
Addict Behav. 1993 Jan-Feb;18(1):35-40
8465674
Br J Addict. 1991 Sep;86(9):1119-27
1932883
Addict Behav. 1989;14(4):379-86
2782121
Clin Pharmacol Ther. 1997 Oct;62(4):453-63
9357397
J Behav Med. 1983 Jun;6(2):207-16
6620373
Psychol Rev. 2004 Jan;111(1):33-51
14756584
J Consult Clin Psychol. 1996 Apr;64(2):366-79
8871421
Psychopharmacology (Berl). 2004 Apr;173(1-2):160-6
14726999
Psychophysiology. 2003 Sep;40(5):776-85
14696731
Nebr Symp Motiv. 1986;34:257-323
3627296
JAMA. 1994 Dec 14;272(22):1749-56
7966923
J Clin Psychiatry. 1996 Nov;57(11):534-8
8968303
Psychophysiology. 1993 May;30(3):261-73
8497555
Psychol Rev. 1990 Jul;97(3):377-95
2200076
Addict Behav. 1984;9(1):95-8
6741672
Psychol Bull. 2003 Mar;129(2):270-304
12696841
Psychopharmacology (Berl). 1996 Aug;126(3):226-33
8876022
Psychophysiology. 1979 Nov;16(6):495-512
515293
Neuropharmacology. 2004;47 Suppl 1:3-13
15464121
Psychopharmacology (Berl). 1982;76(2):139-48
6805024
J Consult Clin Psychol. 1982 Feb;50(1):71-86
7056922
Pharmacol Biochem Behav. 2004 Jul;78(3):647-52
15251274
Behav Neurosci. 1993 Dec;107(6):970-80
8136072
Psychophysiology. 1996 Mar;33(2):103-11
8851238
Br J Addict. 1992 Jul;87(7):1037-40
1643396
Psychol Sci. 2000 Jan;11(1):86-9
11228851
Nicotine Tob Res. 2006 Jun;8(3):379-92
16801296
J Consult Clin Psychol. 1999 Aug;67(4):555-62
10450626
J Consult Clin Psychol. 2002 Feb;70(1):216-27
11860048
Psychophysiology. 1990 Sep;27(5):481-94
2274612